N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Not applicable ClinicalTrials.gov

Manganese-enhanced Magnetic Resonance Imaging in Takotsubo Cardiomyopathy

Sponsor: University of Edinburgh • ClinicalTrials.gov ID: NCT07491718

Registry updated: 2026-09-18
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

The goal of this research study is to further understand the physiological mechanisms involved in a heart condition called takotsubo cardiomyopathy, also known as broken heart syndrome. Furthermore, the investigators will be assessing the effects different cardiac medications have on these physiological mechanisms. This will be achieved by performing cardiac MRI scans using a special dye called manganese. Manganese uptake in the heart is altered in patients with takotsubo cardiomyopathy. The investigators will study the effects that different cardiac medications have on manganese uptake.

Interventions

  • Bisoprolol (Drug)
    Participants will be randomised to receive Bisoprolol medication.
  • Valsartan (Drug)
    Participants will be randomised to receive Valsartan medication.
  • sacubitril/ valsartan (Drug)
    Participants will be randomised to receive Sacubitril/Valsartan medication first.
  • Dapagliflozin (10mg Tab) (Drug)
    Participants will be randomised to receive Dapaglifozin medication first.
  • No medications (Drug)
    Participants will be randomised to receive no study medication.

Eligibility criteria

Inclusion Criteria: * Males and females \>18 years of age * Clinical presentation of takotsubo cardiomyopathy * Have capacity to give formal consent Exclusion Criteria: * Unable to tolerate or contraindication to magnetic resonance imaging * Renal failure (estimated glomerular filtration rate \<30 mL/min/1.73 m2) - this would be assessed by performing a blood test * Prior history of cardiomyopathy * Current pregnancy * Weight greater than 250kg * Severe asthma for study 1 (given Bisoprolol is contraindicated in this condition) * Type 1 diabetes mellitus for study 2 (given Dapaglifozin is contraindicated in this population) * Significant hypotension (given the medications prescribed as part of the study can also cause hypotension as a side effect) * Significant bradycardia for study 1 (given Bisoprolol can exacerbate any pre-existing significant bradycardia) * Prescribed Digoxin (this medication interacts with the Manganese) * Unable to give formal consent

Conditions

Takotsubo Cardiomyopathy

Locations

  • University of Edinburgh — Edinburgh, United Kingdom
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record